Searched for
INDIA PHARMACEUTICALS
Diwali 2026: 77 stocks knock down D-St bears to deliver multibagger returns of up to 4,700% in a yearWith Diwali 2026 on the horizon, 77 stocks have thrived despite market fluctuations, marking exceptional returns. Mrugesh Trading showcases...- India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugsOver the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth ...
- Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosyst...
- Sun Pharma Q2 profit takes a hit on exceptional itemsSun Pharmaceutical has seen a notable 36% drop in net profit, juxtaposed with an 11.8% rise in consolidated revenue. The uplift in revenue ...
- India-Brazil bilateral trade set to reach $20 bn with focus on critical minerals, AI, defence: EnvoyBrazil's Ambassador to India highlighted growing trade relations, expecting bilateral trade to reach USD 20 billion soon. The partnership e...
- Sun Pharma Q2 profit falls 36% as litigation costs hit earningsSun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Reven...
- Sun Pharma ordered to halt eye drug production at Assam plant over quality lapses: ReportIndian regulators have ordered Sun Pharmaceutical Industries to stop manufacturing ophthalmic products at the Assam facility. This decision...
- Sun Pharma Q2 Results: Profit falls 36% YoY to Rs 1,989 crore on exceptional chargesSun Pharma Q2 Results: Revenue from operations rose 12% YoY to Rs 16,199 crore from Rs 14,478 crore in Q2 of last financial year, supported...
- Laurus Labs shares climb 4% after Q2 profit zooms 126% YoYLaurus Labs shares rose 3.79% to Rs 2,329 after the pharmaceutical company reported strong Q2FY27 results. Revenue increased 33% year-on-ye...
- Bombay HC tells Shreya Life to rename antibiotic drugThe Bombay High Court has ordered the removal of Shreya Life Sciences’ antibiotic trademark Lefoxin Biox from the register, ruling that it ...
- India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: PharmexcilIndia's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driv...
- SCHOTT Pharma India marks a new chapter, building on its strong national presence and global capabilitiesNew identity reinforces the company’s focus on innovation, customer partnerships and pharmaceutical drug containment and delivery solutions
- PM Modi reviews projects worth over Rs 16,000 crore across 31 States, UTs at 54th PRAGATI meetingPrime Minister Narendra Modi chaired the 54th PRAGATI meeting to evaluate infrastructure projects worth over Rs 16,000 crore. The meeting f...
- India, Mexico begin talks for trade pact; aim to boost commerce, investmentsIndia and Mexico have initiated negotiations for a preferential trade agreement to enhance bilateral trade and investment. The agreement ai...
- Cipla’s US recovery, biosimilar pipeline key to future growth prospectsCipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its str...
- Cipla sets sights on first-wave gains from rollout of Keytruda BiosimilarCipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for t...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- AI halves drug discovery times, but =trial bottleneck remains a costly realityNovo Nordisk, Sanofi and Dr Reddy’s Laboratories are among the companies exploring applications ranging from drug discovery to laboratory a...
- DRL says cap on trade margins a positive, posts 36% dip in Q2 PATIn the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trad...
- Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select playersIndia's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceuti...
Load More
